The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
about
The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
The CRISPR/Cas9 system efficie ...... l of chronic myeloid leukemia.
@ast
The CRISPR/Cas9 system efficie ...... l of chronic myeloid leukemia.
@en
type
label
The CRISPR/Cas9 system efficie ...... l of chronic myeloid leukemia.
@ast
The CRISPR/Cas9 system efficie ...... l of chronic myeloid leukemia.
@en
prefLabel
The CRISPR/Cas9 system efficie ...... l of chronic myeloid leukemia.
@ast
The CRISPR/Cas9 system efficie ...... l of chronic myeloid leukemia.
@en
P2093
P2860
P50
P921
P356
P1433
P1476
The CRISPR/Cas9 system efficie ...... l of chronic myeloid leukemia.
@en
P2093
Ignacio García-Tuñón
Jesús María Hernández-Rivas
José Luis Ordoñez
María Hernández-Sánchez
Miguel Álamo-Quijada
Rocio Benito
P2860
P304
26027-26040
P356
10.18632/ONCOTARGET.15215
P407
P577
2017-02-09T00:00:00Z